Melinta Therapeutics
| Industry | Broad-spectrum antibiotics |
|---|---|
| Website | melinta |
Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded
Parsippany, New Jersey.[1]
In mid-2011, Sanofi entered into a global research collaboration and licensing option with the company to develop and commercialize novel antibiotics.[2] It was renamed Melinta Therapeutics in 2013.[3]
One of its products,
fluoroquinolone antibiotic acquired from Wakunaga Pharmaceutical in 2006,[2] was approved by the FDA in 2017.[4]
As of 2016, the company was also developing
oxazolidinone for bacterial acne.[3]
Melinta shredded off its discovery research team in late 2018.[5] It also moved its headquarters from New Haven to Morristown, New Jersey in early 2019.
On December 27, 2019, Melinta Therapeutics filed for Chapter 11 bankruptcy protection.[6]
In April 2020, it was transferred to affiliates of its creditor Deerfield Management.[5]
References
- ^ Carroll, John (2011). "Rib-X Pharmaceuticals - 2011 Fierce 15". FierceBiotech.
- ^ doi:10.3833/pdr.v2011i7.1494 (inactive 31 January 2024). Archived from the original on 25 April 2012.)
{{cite news}}: CS1 maint: DOI inactive as of January 2024 (link - ^ a b Stearns, John (August 1, 2016). "Melinta Therapeutics takes aim at deadly drug-resistant bacteria". Hartford Business Journal.
- ^ Osborne, Randy (20 June 2017). "Melinta's I.V., oral delafloxacin wins FDA nod in skin infections". BioWorld. Archived from the original on 3 August 2019. Retrieved 10 July 2017.
- ^ a b Missakian, Natalie (April 23, 2020). "Antibiotics maker Melinta emerges from bankruptcy under new ownership". Hartford Business. Retrieved 23 November 2022.
- ^ "Antibiotics maker Melinta files for Chapter 11 bankruptcy". Reuters. 2019-12-27. Retrieved 2019-12-29.
